Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)

Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors. The growing prevalence of CKD with or without type 2 diabetes in China imposes a significant burden on both the general population and the healthcare system. This market includes a diverse array of antihypertensive agents and SGLT-2 inhibitors, which are used to slow the progression of kidney damage. Dapagliflozin (AstraZeneca’s Forxiga) and empagliflozin (Eli Lilly’s Jardiance, generics) are becoming the standard of care in CKD treatment in China. The recent introduction of Bayer’s Kerendia (finerenone) and the expected approval of Novo Nordisk’s Ozempic (semaglutide) are set to drive market growth throughout the 2024-2034 forecast period. This report analyzes how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL), and the entry of generics or biosimilars—will influence the launch and uptake of new and existing therapies.

QUESTIONS ANSWERED

• What is the diagnosed prevalence of CKD in China, and how are CKD patients treated?
• What are interviewed experts’ insights into current treatment options?
• What are the key unmet needs in the management of CKD in China?
• What are the key market access considerations, and how will they affect the uptake of emerging therapies for CKD in China?
• What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
• Gauge the commercial outlook and impact of key market events.

Primary Research

Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 nephrologists in China

Epidemiology

Diagnosed prevalence of chronic kidney disease patients in urban versus rural China: clinically relevant and commercially relevant drug-treatable populations

Forecast

10-year, annualized, drug-level sales and patient share of key chronic kidney disease therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions

Drug treatments

Coverage of key current and late-phase emerging therapies

Custom drug modeler

Integrated tool to input customized forecast assumptions (e.g., launch date, price)